Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL)
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma
Initial treatment options for relapsed/refractory multiple myeloma patients
Latest in advanced endometrial cancer
OncoAlert and ecancer weekly round up for November 29th - December 5th, 2021
Post-HSCT management of ALL - Adult ALL perspective
Latest in diagnostics in EGFR mutated NSCLC
Cancer drug policy and access in LMICs
Paediatric ALL perspective
Latest in Philadelphia chromosome-positive ALL (Ph+ ALL)
Optimal use of asparaginase for acute lymphoblastic leukaemia